Effects of Iguratimod Combined with Methotrexate on Angiogenesis-related Cytokines of Patients with Refractory Rheumatoid Arthritis
10.3870/j.issn.1004-0781.2016.02.011
- VernacularTitle:艾拉莫德联合甲氨蝶呤对难治性类风湿关节炎患者血管新生相关细胞因子的影响
- Author:
Deqian MENG
;
Wenyou PAN
;
Yan LIU
;
Zhen JIANG
;
Ju LI
;
Hui LI
;
Shanshan LIU
;
Yongsheng LI
;
Yuling CHENG
- Publication Type:Journal Article
- Keywords:
Iguratimod;
Methothexate;
Rheumatoid arthritis;
Vascular endothelial growth factor;
Endostatin
- From:
Herald of Medicine
2016;(2):153-156
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of iguratimod ( IT) combined with methotrexate ( MTX) in patients with refractory rheumatoid arthritis ( rRA) . Methods Sixty patients with rRA were randomly divided into 2 groups ( n=30 each group) . The cases in treatment group received 50 mg.d-1 of iguratimod and 10 mg of MTX for 16 weeks. The cases in control group were treated by 10-15 mg of MTX. DAS28 was analyzed. Levels of VEGF and endostatin ( ES) were quantified. Results In the treatment group,after 16-week treatment,DAS28,levels of VEGF and ES were (3.0±1.2),(818.9±178.8) pg.mL-1, (337.8±132.6) ng.mL-1,and those in the control group were (5.7±1.9),(1000.2±245.9) pg.mL-1,(253.8±77.8) ng.mL-1,respectively. In the treatment group,DAS28 and VEGF after the treatment were significantly decreased as compared with those before the treatment ( P<0.01) . The decrement was more significant in the treatment group than in the control group ( P<0.01) . At the 16th week of treatment,ES was significantly increased as compared with that before the treatment ( P<0.01) , and there was a significant difference between the treatment group and the control group (P<0.01). Conclusion Iguratimod combined with MTX have a prominent effect on rRA with high safety. The efficacy of IT on RA might be related with decreasing VEGF release,increasing ES production and alleviating synovium angiogenesis.
